Latest news with #JanusHendersonInvestors
Associated Press
4 days ago
- Business
- Associated Press
Forum Investment Group Strengthens Credit Platform with New Head of Debt
DENVER--(BUSINESS WIRE)--Jun 4, 2025-- Forum Investment Group is pleased to announce that Jason Brooks has joined the firm as Head of Debt, bringing more than 22 years of capital markets, real estate securities, and investment management experience to the organization. In this newly created leadership role, Jason will oversee all aspects of Forum's public credit-related investment activities and strategies, helping to scale the firm's credit platform and expand its capabilities in real estate lending and structured finance. Throughout his career, Jason has built a reputation for deep credit experience, rigorous underwriting, and strong investment performance across public and private markets. Prior to joining Forum, Jason spent over 12 years at Janus Henderson Investors as a Portfolio Manager and Global Securitized Products Analyst, where he led research and investment selection across a range of securitized fixed income strategies, including CMBS and ABS. He played a key role in managing multi-billion-dollar portfolios and driving risk-adjusted returns through market cycles. Prior to Janus Henderson Investors, Jason served as Director of Structured Securities at TIAA-CREF, where he led CMBS research and contributed to the construction and management of fixed income mutual funds. Early in his career, as an Associate at Gramercy Capital Corp, Jason's responsibilities included asset selection, surveillance, and structural leadership on both cash and synthetic securitizations backed by commercial real estate assets. 'Jason brings a valuable combination of institutional investment discipline and real estate credit depth that will be instrumental as we expand our debt strategies,' said Lee Beck, President of Forum Investment Group. 'His ability to navigate complex capital structures and assess risk across the real estate and securitized landscape will enhance the value we deliver to our investors and borrowers.' 'I'm excited to join Forum at such a pivotal time in the firm's growth,' said Jason Brooks. 'Forum's integrated platform and long-term investment approach create a strong foundation for expanding our credit strategies. I look forward to building on that momentum and helping to deliver innovative, risk-aware debt solutions that support both our investors and real estate partners.' About Forum: Forum Investment Group ('Forum') is a Denver-based boutique investment management firm dedicated to empowering individual investors by investing through real estate cycles. With assets in over 20 states, Forum built its foundation in development and evolved into acquisition and financing, providing access to a range of real estate investments. For more information, please visit View source version on CONTACT: Media Contact: Edward Lopez Profile Advisors P: 646-818-9018 E:[email protected] KEYWORD: COLORADO UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PROFESSIONAL SERVICES COMMERCIAL BUILDING & REAL ESTATE FINANCE CONSTRUCTION & PROPERTY ASSET MANAGEMENT BANKING SOURCE: Forum Investment Group Copyright Business Wire 2025. PUB: 06/04/2025 11:06 AM/DISC: 06/04/2025 11:05 AM
Business Wire
4 days ago
- Business
- Business Wire
Forum Investment Group Strengthens Credit Platform with New Head of Debt
DENVER--(BUSINESS WIRE)--Forum Investment Group is pleased to announce that Jason Brooks has joined the firm as Head of Debt, bringing more than 22 years of capital markets, real estate securities, and investment management experience to the organization. In this newly created leadership role, Jason will oversee all aspects of Forum's public credit-related investment activities and strategies, helping to scale the firm's credit platform and expand its capabilities in real estate lending and structured finance. Throughout his career, Jason has built a reputation for deep credit experience, rigorous underwriting, and strong investment performance across public and private markets. Prior to joining Forum, Jason spent over 12 years at Janus Henderson Investors as a Portfolio Manager and Global Securitized Products Analyst, where he led research and investment selection across a range of securitized fixed income strategies, including CMBS and ABS. He played a key role in managing multi-billion-dollar portfolios and driving risk-adjusted returns through market cycles. Prior to Janus Henderson Investors, Jason served as Director of Structured Securities at TIAA-CREF, where he led CMBS research and contributed to the construction and management of fixed income mutual funds. Early in his career, as an Associate at Gramercy Capital Corp, Jason's responsibilities included asset selection, surveillance, and structural leadership on both cash and synthetic securitizations backed by commercial real estate assets. 'Jason brings a valuable combination of institutional investment discipline and real estate credit depth that will be instrumental as we expand our debt strategies,' said Lee Beck, President of Forum Investment Group. 'His ability to navigate complex capital structures and assess risk across the real estate and securitized landscape will enhance the value we deliver to our investors and borrowers.' 'I'm excited to join Forum at such a pivotal time in the firm's growth,' said Jason Brooks. 'Forum's integrated platform and long-term investment approach create a strong foundation for expanding our credit strategies. I look forward to building on that momentum and helping to deliver innovative, risk-aware debt solutions that support both our investors and real estate partners.' About Forum: Forum Investment Group ('Forum') is a Denver-based boutique investment management firm dedicated to empowering individual investors by investing through real estate cycles. With assets in over 20 states, Forum built its foundation in development and evolved into acquisition and financing, providing access to a range of real estate investments. For more information, please visit
Yahoo
27-05-2025
- Business
- Yahoo
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ('Shares') of its common stock ('Common Stock') or, in lieu thereof, to certain investors, pre-funded warrants ('Pre-Funded Warrants') to purchase 6,963,556 shares of Common Stock, in a private placement. Each full Share (or Pre-Funded Warrant in lieu thereof) will be accompanied by a warrant (a 'Common Warrant') to purchase one-half of a share of Common Stock. The purchase price for each Share and accompanying Common Warrant will be $2.8825 (or $2.8824 for each Pre-Funded Warrant and accompanying Common Warrant). Lexeo anticipates the gross proceeds from the private placement to be approximately $80 million, before deducting any offering related expenses. The private placement is expected to close on May 28, 2025, subject to customary closing conditions. The Pre-Funded Warrants will have an exercise price of $0.0001 per share until exercised in full, and the Common Warrants will have an exercise price of $2.82 per share and expire on May 28, 2029. The private placement was co-led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors, including Adar1 Capital Management, Affinity Healthcare Fund, LP, Ally Bridge Group, Coastlands Capital, Surveyor Capital (a Citadel company), Vestal Point Capital, and Woodline Partners LP. 'This financing will enable Lexeo to build on its leadership in cardiac genetic medicines as we continue to advance our clinical stage pipeline,' said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. 'With the support of an exceptional group of new and existing long-term investors, we believe we remain well-positioned to accelerate development of our programs and drive innovation with next-generation therapies that could redefine the treatment paradigm for devastating cardiovascular conditions.' J.P. Morgan and Oppenheimer & Co. acted as co-lead placement agents for the transaction. Baird also acted as placement agent. Lexeo intends to use net proceeds from the private placement to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes. The proceeds from this private placement, combined with current cash, cash equivalents and marketable securities are expected to fund Lexeo's operating and capital expenditures into 2028. The securities to be sold in this private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state or other applicable jurisdiction's securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Concurrently with the execution of the securities purchase agreement, Lexeo and the investors entered into a registration rights agreement pursuant to which the company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the 'SEC') registering the resale of the Shares and Common Stock underlying the Pre-Funded Warrants and Common Warrants(together, the 'Warrant Shares') sold in the private placement. Any offering of the Shares and Warrant Shares under the resale registration statement will only be made by means of a prospectus. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Company's securities, nor shall there be any offer, solicitation, or sale of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the 'Minimum Price' requirement (as defined in the Nasdaq rules). About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others for devastating diseases with high unmet need. Cautionary Note Regarding Forward-Looking StatementsCertain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws, including, but not limited to, statements regarding the expected closing of the private placement, anticipated receipt, impact and use of proceeds from the private placement, whether the conditions for the closing of the private placement will be satisfied, the filing of a registration statement or final prospectus, as applicable, to register the resale of the Shares and Warrant Shares to be issued and sold in the private placement, the anticipated cash runway following closing of the private placement , and other information that is not historical information. Words such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'develop,' 'plan' or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo's filings with the SEC), many of which are beyond the company's control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo's preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo's Annual Report on Form 10-K for the annual period ended December 31, 2024, filed with the SEC on March 24, 2025, Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 12, 2025, as amended, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Media Response:Media@ Investor Response:Carlo Tanzi, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Tariffs Expected to Trigger More Market Volatility
Ali Dibadj, CEO of Janus Henderson Investors, joined the C-Suite on Bloomberg Open Interest to talk about how the geopolitical trade realignment will hit global markets. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Janus CEO: CLO ETFs Held Strong Amid Market Volatility
CLO ETFs experienced no 'dislocations or surprises' during the April volatility, and the structures behaved 'exactly as we had anticipated,' said Ali Dibadj, CEO of Janus Henderson Investors. As reported by Bloomberg and the Financial Times, CLO ETFs listed in the U.S. swung to wide discounts in early April—on average, more than 1% on April 4—as investors made large withdrawals during the market volatility. Even the $20 billion Janus Henderson AAA CLO ETF (JAAA), by far the world's largest CLO ETF, was changing hands more than 1% below its net asset value (NAV). CLOs, or collateralized loan obligations, are securities providing exposure to an actively managed pool of loans made to companies—typically private equity. The CLO pool is then sliced into tranches, ranging in seniority from AAA to equity, with each tranche enjoying different claims on the cash flows of the loans as well as protections from credit losses. JAAA Leads Among CLO ETFs JAAA launched in October 2020 and has demonstrated very strong asset-gathering ability. Janus Henderson boasts roughly an 80% market share in the category. Speaking at the group's first-quarter earnings call, Dibadj said, 'Investors in this ETF … tend to be medium- to long-term holders. That said, there are also some shorter-term investors, and that is where you can see the turnover in the market that creates the volatility.' The outflows highlighted that ETFs with somewhat illiquid underlying securities can detach from NAV in stressed scenarios, with the ETF itself acting as a price-discovery mechanism. For Dibadj, however, the redemptions from Janus Henderson's ETFs were soaked up as expected, with 'very little impact' on the CLO market or the underlying portfolio. 'We have seen no dislocations or surprises. In fact, we have been quite pleased with how the market reacted—in a very measured and disciplined way—exactly as we had anticipated, even given the scale of our position.' Janus Henderson debuted a European iteration of JAAA in January, and the fund has gathered $101 million in assets since inception. This article was originally published at sister publication ETF Stream. Permalink | © Copyright 2025 All rights reserved
